PRL3-ZUMAB is under clinical development by Intra-Immusg and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRL3-ZUMAB’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRL3-ZUMAB is under development for the treatment of relapsed/refractory acute myeloid leukemia, relapsed/refractory multiple myeloma, hepatocellular carcinoma, gastric cancer and other solid tumors. The drug candidate is administered as infusion. It acts by targeting protein tyrosine phosphatase of regenerating liver 3 (PRL-3).
For a complete picture of PRL3-ZUMAB’s drug-specific PTSR and LoA scores, buy the report here.